宁心宝胶囊联合达比加群酯治疗非瓣膜性心房颤动的治疗效果  

Therapeutic Effects of Ningxinbao Capsules Combined with Dabigatran Etexilate in the Treatment of Non-Valvular Atrial Fibrillation

作　　者：刘静雅 吴泽阳 朱佳 杨宁 刘凤仙 王晓微 LIU Jingya;WU Zeyang;ZHU Jia;YANG Ning;LIU Fengxian;WANG Xiaowei(Dept.of Pharmacy,Zhangjiakou the First Hospital,Hebei Zhangjiakou 075000,China;Dept.of Cardiology,Zhangjiakou the First Hospital,Hebei Zhangjiakou 075000,China;Dept.of Endocrinology,General Universal China Railway Shanqiao Hospital,Hebei Qinhuangdao 066205,China)

机构地区：[1]张家口市第一医院药剂科,河北张家口075000 [2]张家口市第一医院心内科,河北张家口075000 [3]通用环球中铁山桥医院内分泌科,河北秦皇岛066205

出　　处：《中国医院用药评价与分析》2022年第8期964-968,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：河北省中医药管理局科研计划项目(No.2022527)。

摘　　要：目的:探讨宁心宝胶囊联合达比加群酯治疗非瓣膜性心房颤动的效果。方法:纳入2019年8月至2020年9月张家口市第一医院心血管内科收治的非瓣膜性心房颤动患者130例作为研究对象,采用随机数字表法分为观察组(n=65)、对照组(n=65)。对照组患者采用达比加群酯治疗,观察组患者在对照组的基础上加用宁心宝胶囊。观察两组患者的临床疗效,治疗前后血管内皮功能[循环内皮细胞(CEC)、内皮素-1(ET-1)和血管性血友病因子(vWF)]、凝血状态[活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、纤维蛋白原(FIB)和凝血酶时间(TT)]、心功能指标[左心室射血分数(LVEF)、心输出量(CO)和心脏指数(CI)]水平,生活质量、栓塞和出血风险以及生存情况。结果:观察组患者的治疗总有效率为89.29%(50/56),明显高于对照组的71.43%(40/56),差异有统计学意义(P<0.05)。治疗后,观察组患者CEC、ET-1和vWF水平明显低于对照组,APTT、PT和TT较对照组明显延长,FIB水平明显高于对照组,LVEF、CO和CI水平明显高于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组患者生活质量各项评分及总分明显高于对照组,差异均有统计学意义(P<0.05)。观察组患者治疗6个月、12个月的栓塞事件、出血事件发生率均低于对照组,差异均有统计学意义(P<0.05);两组患者12个月生存率的差异无统计学意义(P>0.05)。结论:宁心宝胶囊联合达比加群酯治疗非瓣膜性心房颤动的疗效较好,可保护心脏,减轻血管内皮功能、凝血功能损伤,提高生活质量,降低出血风险。OBJECTIVE:To probe into the therapeutic effects of Ningxinbao capsules combined with dabigatran etexilate in the treatment of non-valvular atrial fibrillation.METHODS:A total of 130 patients with non-valvular atrial fibrillation admitted into the cardiovascular medicine department of Zhangjiakou the First Hospital from Aug.2019 to Sept.2020 were extracted to be divided into the observation group(n=65)and the control group(n=65)via the random number table.The control group was treated with dabigatran etexilate,while the observation group was additionally given Ningxinbao capsules based on the control group.The clinical efficacy,vascular endothelial function[circulating endothelial cell(CEC),endothelin-1(ET-1)and von Willebrand factor(vWF)],coagulation status[activated partial thromboplastin time(APTT),prothrombin time(PT),fibrinogen(FIB)and thrombin time(TT)],cardiac function indicators[left ventricular ejection fraction(LVEF),cardiac output(CO)and cardiac index(CI)],quality of life,embolism and bleeding risk and survival status before and after treatment were compared between two groups.RESULTS:The total effective rate of the observation group was 89.29%(50/56),significantly higher than that of the control group(71.43%,40/56),the difference was statistically significant(P<0.05).The levels of CEC,ET-1 and vWF in the observation group after treatment were lower than those in the control group,the APTT,PT and TT in the observation group after treatment were significantly longer than those in the control group,yet the FIB was higher than that in the control group,LVEF,CO and CI were higher than those of the control group,the differences were statistically significant(P<0.05).After treatment,the scores and total scores of quality of life in the observation group were significantly higher than those in the control group,the difference was statistically significant(P<0.05).The incidence of embolism events and bleeding events in the observation group were lower than those in the control group after 6 months and 12 months

关 键 词：宁心宝胶囊 达比加群酯 非瓣膜性心房颤动 出血风险 

分 类 号：R932[医药卫生—生药学]